Ipca Labs board approves merger of Krebs Biochemicals

Listed Co AcquisitionNclt Scheme FiledStrategic Transactions View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+5.4%1-day move

₹1619.90

prior close

₹1618.30

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+0.8+1.2+2.1+5.4+4.8+6.3+9.6+9.9+8.9+13.0———

Up moveDown movePending

AI summary

Ipca Labs board approved merging Krebs Biochemicals into itself. Ipca's FY26 standalone income was Rs. 7,431 crore; Krebs earned Rs. 26 crore mostly from Ipca. No cash is paid - Krebs shareholders get 7 Ipca shares for every 200 Krebs shares held. The deal brings Krebs's fermentation-based API capability, which Ipca currently lacks. Promoter holding dips slightly from 44.72 to 44.66 percent. Subject to NCLT and SEBI approvals.

Likely market impact

Small deal by size but strategic - secures a key API supply and adds fermentation capability. Marginal equity dilution, needs approvals.